Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73


Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR.

Tennstedt P, Bölch C, Strobel G, Minner S, Burkhardt L, Grob T, Masser S, Sauter G, Schlomm T, Simon R.

Int J Oncol. 2014 Feb;44(2):609-15. doi: 10.3892/ijo.2013.2200. Epub 2013 Nov 29.


Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells.

Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C, Giebel J, Walther R.

FEBS J. 2008 Nov;275(22):5703-13. doi: 10.1111/j.1742-4658.2008.06697.x.


Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.

Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A.

Int J Cancer. 2005 Dec 20;117(6):1049-54.


Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.

Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, Byrne JA.

Clin Cancer Res. 2008 Aug 15;14(16):5050-60. doi: 10.1158/1078-0432.CCR-07-4994.


Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer.

Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C.

BMC Cancer. 2011 Jan 12;11:14. doi: 10.1186/1471-2407-11-14.


A testis-specific and testis developmentally regulated tumor protein D52 (TPD52)-like protein TPD52L3/hD55 interacts with TPD52 family proteins.

Cao Q, Chen J, Zhu L, Liu Y, Zhou Z, Sha J, Wang S, Li J.

Biochem Biophys Res Commun. 2006 Jun 9;344(3):798-806. Epub 2006 Apr 19.


PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.

Wang R, Xu J, Saramäki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, Chung LW.

Cancer Res. 2004 Mar 1;64(5):1589-94.


Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Byrne JA, Frost S, Chen Y, Bright RK.

Tumour Biol. 2014 Aug;35(8):7369-82. doi: 10.1007/s13277-014-2006-x. Epub 2014 May 6. Review.


Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer.

Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, Naya Y, Ichikawa T, Seki N.

FEBS Lett. 2014 May 21;588(10):1973-82. doi: 10.1016/j.febslet.2014.04.020. Epub 2014 Apr 24.


Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM.

Cancer Res. 2004 Jun 1;64(11):3814-22.


MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM.

BMC Cancer. 2010 Sep 17;10:497. doi: 10.1186/1471-2407-10-497.


Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI.

Tiacci E, Orvietani PL, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V, Martelli MP, Liso A, Benedetti R, Pacini R, Bolli N, Pileri S, Pulford K, Gambacorta M, Carbone A, Pasquarello C, Scherl A, Robertson H, Sciurpi MT, Alunni-Bistocchi G, Binaglia L, Byrne JA, Falini B.

Blood. 2005 Apr 1;105(7):2812-20. Epub 2004 Dec 2.


Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.

Christoph F, Müller M, Schostak M, Soong R, Tabiti K, Miller K.

Urology. 2004 Jul;64(1):157-61.


Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.

Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.


Decreased fragile histidine triad gene messenger RNA expression in lung cancer.

Sasaki H, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Clin Lung Cancer. 2006 May;7(6):412-6.


Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.

D'Cunha J, Corfits AL, Herndon JE 2nd, Kern JA, Kohman LJ, Patterson GA, Kratzke RA, Maddaus MA.

J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491.


Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.

Bagley RG, Rouleau C, Weber W, Mehraein K, Smale R, Curiel M, Callahan M, Roy A, Boutin P, St Martin T, Nacht M, Teicher BA.

Microvasc Res. 2011 Nov;82(3):253-62. doi: 10.1016/j.mvr.2011.09.004. Epub 2011 Sep 17.


Supplemental Content

Support Center